Want to see GB:FAB full AI Analyst Report?
Fusion Antibodies Plc (FAB) AI Stock Analysis
Fusion Antibodies Plc
(LSE:FAB)
The score is primarily constrained by persistent losses and substantial cash burn. Bearish technical positioning and the negative P/E ratio add further risk, while recent revenue and gross-margin improvement and low leverage provide only limited support.
Fusion Antibodies Plc (FAB) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 7.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 536.10K
- Price to Earnings (P/E)
- -6.1
- Beta (1Y)
- -0.65
- Revenue Growth
- 7.38%
- EPS Growth
- 44.13%
- Country
- UK
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Fusion Antibodies Plc Business Overview & Revenue Model
Company Description
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology a...
How the Company Makes Money
Fusion Antibodies makes money primarily by selling fee-for-service R&D and development work to external customers on a project basis. Key revenue streams typically include: (1) Contract antibody discovery and generation work, where clients pay for th...
Fusion Antibodies Plc Financial Statement Overview
Summary
Persistent operating and net losses, ongoing negative operating and free cash flow, and continued funding needs outweigh recent revenue recovery, improved gross margin, and low leverage.
Income Statement
35NegativeBalance Sheet
45NeutralCash Flow
28Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.11M | 2.11M | 1.97M | 1.14M | 2.90M | 4.80M |
| Gross Profit | 1.10M | 1.10M | 430.00K | -265.00K | 202.00K | 1.72M |
| EBITDA | -1.51M | -1.85M | -1.62M | -2.06M | -2.48M | -573.00K |
| Net Income | -1.15M | -1.15M | -1.71M | -2.23M | -2.60M | -1.20M |
Balance Sheet | ||||||
| Total Assets | 2.73M | 2.73M | 1.32M | 2.42M | 2.06M | 4.92M |
| Cash, Cash Equivalents and Short-Term Investments | 1.04M | 1.04M | 359.00K | 1.20M | 195.00K | 2.05M |
| Total Debt | 331.00K | 331.00K | 20.00K | 43.00K | 75.00K | 69.00K |
| Total Liabilities | 1.10M | 1.10M | 654.00K | 627.00K | 939.00K | 1.23M |
| Stockholders Equity | 1.62M | 1.62M | 669.00K | 1.79M | 1.12M | 3.68M |
Cash Flow | ||||||
| Free Cash Flow | -1.17M | -1.17M | -1.37M | -1.77M | -1.87M | -591.00K |
| Operating Cash Flow | -1.11M | -1.11M | -1.36M | -1.77M | -1.75M | -333.00K |
| Investing Cash Flow | -60.00K | -60.00K | -5,000 | 1,000 | -114.00K | -258.00K |
| Financing Cash Flow | 1.85M | 1.85M | 529.00K | 2.77M | 7,000 | -46.00K |
Fusion Antibodies Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FAB, the sentiment is Negative. The current price of 6.00 is below the 20-day moving average (MA) of 7.59, below the 50-day MA of 9.86, and below the 200-day MA of 11.99, indicating a bearish trend. The MACD of -1.31 indicates Positive momentum. The RSI at 30.21 is Neutral, neither overbought nor oversold. The STOCH value of 62.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FAB.
Fusion Antibodies Plc Peers Comparison
Overall Rating
GB:BVXP89Outperform
GB:APTA43Neutral
GB:AVCT43Neutral
GB:SCLP43Neutral
GB:GENF42Neutral- GB:FAB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:BVXP | 89Outperform | GBP 104.50M | 13.79 | 67.81% | 7.50% | -1.10% | 0.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:APTA | 43Neutral | GBP 10.23M | -9.83 | -46.61% | ― | 28.35% | 57.14% |
| GB:AVCT | 43Neutral | GBP 294.51M | -6.63 | -1293.07% | ― | ― | ― |
| GB:SCLP | 43Neutral | GBP 105.95M | -4.99 | 128.87% | ― | -100.00% | -30.39% |
| GB:GENF | 42Neutral | GBP 10.85M | -8.29 | 609.63% | ― | ― | 56.00% |
| GB:FAB | 39Underperform | GBP 7.51M | -6.06 | -97.87% | ― | 7.38% | 44.13% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:FAB | Fusion Antibodies Plc | 6.00 | -7.50 | -55.56% | |
| GB:AVCT | Avacta Group plc | 60.50 | -11.50 | -15.97% | |
| GB:BVXP | Bioventix plc | 2000.00 | -17.66 | -0.88% | |
| GB:SCLP | Scancell Holdings | 87.40 | -11.10 | -11.27% | |
| GB:GENF | Genflow Biosciences Plc | 1.82 | -0.25 | -12.05% | |
| GB:APTA | Aptamer Group Plc | 0.29 | -0.51 | -63.13% |
Fusion Antibodies Plc Corporate Events
Fusion Antibodies wins complex antibody project from major pharma client
PositiveFusion Antibodies plc has secured a new contract from a US-based specialty division of a global pharmaceutical company to deliver transient gene expression of the client’s lead antibody followed by a cryogenic electron microscopy study. The pro...
Fusion Antibodies Wins Complex Antibody Development Contract with Global Pharma Client
PositiveFusion Antibodies plc, a Belfast-based CRO focused on antibody engineering and pre-clinical development for therapeutic and diagnostic uses, provides end-to-end services from antibody generation and humanisation to stable cell line production. The AI...
Fusion Antibodies AGM Resolutions Passed as Company Targets Expanding Antibody Market
PositiveFusion Antibodies plc, a specialist in antibody engineering and pre-clinical discovery services for pharma and diagnostics clients, reported that all resolutions at its annual general meeting were duly passed. The Belfast-based CRO, listed on AIM, co...
Fusion Antibodies Warns on H1 Trading but Flags Progress in DR5 Programme and OptiMAL Platform
NegativeFusion Antibodies has reported a sharp decline in first-half trading, with unaudited H1 FY27 revenues falling to about £457,000 from £838,000 a year earlier and gross margin compressed to 10% amid difficult market conditions. Cash at 30 Sep...
Fusion Antibodies launches revamped customer-focused website to showcase antibody services
PositiveFusion Antibodies plc, a specialist in pre-clinical antibody discovery and engineering, has launched a redesigned customer-focused website aimed at better presenting its discovery, engineering and supply capabilities. The updated site is designed to...
Fusion Antibodies Publishes 2026 Annual Report and Sets AGM Date
NeutralFusion Antibodies plc, a specialist in antibody engineering and related contract research services for pharmaceutical and diagnostic companies, has built a strong track record in antibody generation and humanisation using its proprietary technologies...
Fusion Antibodies boosts margins and cash as OptiMAL launch and patents strengthen growth platform
PositiveFusion Antibodies reported audited revenues of £2.1 million for the year to 31 March 2026, with underlying service revenue of £1.86 million and second-half revenue up 21% versus the first half. The company’s gross margin rose sharply...
Fusion Antibodies boosts margins and cash as OptiMAL launch and patents advance
PositiveFusion Antibodies reported audited revenues of £2.1m for the year to 31 March 2026, with underlying service revenue of £1.86m and a 21% second-half uplift that helped lift gross margin to 53%. The operating loss narrowed to £1.13m desp...
Fusion Antibodies Wins Canadian Patent for OptiMAL Antibody Library
PositiveFusion Antibodies plc, a Belfast-based CRO focused on antibody engineering for therapeutic and diagnostic use, provides end-to-end services spanning antibody generation, development, production, characterisation and optimisation. The AIM-traded compa...
Fusion Antibodies to unveil annual results with open investor presentation
PositiveFusion Antibodies Plc, a Belfast-based specialist in pre-clinical antibody discovery and engineering, operates as a contract research organisation serving therapeutic and diagnostic markets. The AIM-listed company offers end-to-end antibody generatio...
Fusion Antibodies Secures Australian Acceptance for Antibody Library Patent
PositiveFusion Antibodies has received a notice of acceptance from IP Australia for its Australian patent application covering an antibody library and associated design methods. The patent, once granted, is expected to enhance the company’s Opti-design...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026